Alvogen has built a regional platform for growth across the APAC region through its subsidiary Lotus Pharmaceuticals.
Lotus primary focus is on the development and manufacturing of high-value generic oncology products for global markets. Lotus is listed on the GreTai Stock Exchange in Taiwan (1795.TWI) with commercial footprint across emerging markets in the APAC region and manufacturing and research centers in Korea and Taiwan.
Broad range of countries
Alvogen’s Asia Pacific commercial hub currently encompasses a broad range of countries including Korea, Taiwan, Myanmar, Thailand, Vietnam, Philippines, Singapore, Malaysia, Hong Kong and China. Alvogen has manufacturing and R&D hubs in Korea and Taiwan.
Petar Vazharov is the Executive Vice President of Asia Pacific. He joined Alvogen in December 2009, after nine years with the generic pharmaceuticals company Actavis Group in various roles – Sales Representative, Division Head in Central Marketing and Senior Manager in Global Business Development.
"In a short period of time, we have built a strong platform for growth in Asia. We have made significant investments in high quality manufacturing and the successful integration of Kunwha, Dream pharma and Lotus. Our strong regional management team will drive our business forward and leverage on our growing global pipeline and geographical reach.”
EVP of Sales in Asia Pacific
Alvogen has commercial operations in 20 countries, including China, Hong Kong, Iceland, India, Luxembourg, Malaysia, Malta, USA, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam, as well as regional hubs, manufacturing and R&D capabilities in the U.S. and South Korea.